Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM | BSE: 500420 | ISIN: INE685A01028 | Industry: Pharmaceuticals
| Expensive Performer
3584.0000 -0.30 (-0.01%)
NSE Sep 02, 2025 11:56 AM
Volume: 45,669
 

3584.00
-0.01%
HDFC Securities
Owing to the enhanced business mix, which will ensure the sustainability of future cash flows, we have increased our assigned earnings multiple from 20x to 22x, and maintain BUY with a TP of Rs 1,480 (22x Sep-19E). After the acquisition of Unichem Labs (UL) domestic portfolio, Torrent Pharma (TRP) will become the fifth largest player in the Rs 1.14tn Indian Pharma market (IMS data). Closed at a value of Rs 36bn, this deal will (1) Further strengthen TRPs position in CVS, CNS and GI categories owing to a complementary sub-therapy presence, (2) Add ~3,000 employees (including MRs) and provide access to an additional 2,100 stockists pan-India, (3) Give TRP an entry into the Indian OTC market, with the growing Unienzyme brand of UL.
Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 3614.9
More from Torrent Pharmaceuticals Ltd.
Recommended